Management of Elevated Testosterone Levels

Diagnostic Evaluation

• Initial workup should include a comprehensive hormonal panel to determine the source of elevated testosterone, including luteinizing hormone (LH) levels, follicle-stimulating hormone (FSH) levels, prolactin levels, and estradiol levels, as recommended by The Journal of Urology 1, 2
• Imaging studies, such as pituitary MRI or adrenal imaging, may be necessary to identify potential causes of elevated testosterone, with a strength of evidence supported by The Journal of Urology 1, 3

Common Causes to Investigate

• Endocrine disorders, such as congenital adrenal hyperplasia, androgen-secreting tumors, and polycystic ovary syndrome, can cause elevated testosterone levels, according to The Journal of Urology 1, 3
• Testosterone replacement therapy at excessive doses can also lead to elevated testosterone levels, as noted by Praxis Medical Insights 2

Management Approach

• Discontinuation of exogenous testosterone or anabolic steroids is necessary, with gradual tapering to prevent withdrawal symptoms, as recommended by Praxis Medical Insights 2
• Referral to endocrinology is essential for management of underlying endocrine disorders, with treatment depending on specific etiology, according to The Journal of Urology 1, 3

Monitoring and Follow-up

• Regular laboratory monitoring, including testosterone levels, complete blood count, and lipid profile, is necessary to assess the effectiveness of treatment and potential complications, as recommended by The Journal of Urology and Praxis Medical Insights 2, 4, 5
• Cardiovascular risk assessment, including monitoring of blood pressure and lipid profiles, is crucial in patients with elevated testosterone levels, according to The Journal of Urology and Praxis Medical Insights 2, 5

Potential Complications of Untreated Elevated Testosterone

• Cardiovascular complications, such as increased risk of atherosclerosis, adverse lipid profile changes, and thrombotic events, can occur with untreated elevated testosterone, as noted by The Journal of Urology and Praxis Medical Insights 2, 5
• Reproductive and hormonal effects, including suppression of natural hormone production, fertility issues, and gynecomastia, can also occur, according to The Journal of Urology and Praxis Medical Insights 2, 6

Management of Elevated Testosterone Levels in Adult Males

Initial Diagnostic Evaluation and Monitoring

• For men over 40, the American Urological Association recommends monitoring PSA levels to screen for prostate abnormalities 7
• The American College of Physicians suggests adjusting dosing regimen to achieve testosterone levels within normal range if exogenous testosterone is identified as the cause 8

Fertility Considerations

• The American Urological Association notes that elevated testosterone can suppress spermatogenesis, and discusses fertility preservation options if relevant 9

Laboratory Monitoring

• The Journal of Urology recommends regular laboratory monitoring, including liver function tests, to assess the effectiveness of treatment 9

Management of Endogenous Hypertestosteronemia

Diagnostic Evaluation

• The American Urological Association recommends measuring hematocrit/hemoglobin at baseline, as elevated testosterone can cause polycythemia, with levels above 50% warranting investigation before any intervention 10, 11, 12
• The American Urological Association suggests checking PSA in men over 40 years to exclude occult prostate pathology, as testosterone elevation may unmask or promote prostate disease 10, 11, 12

Imaging Studies

• The Endocrine Society recommends ordering pituitary MRI if LH is low or prolactin is elevated to investigate for pituitary adenomas or other sellar masses that could cause hormonal dysregulation 13

Treatment Approach

• The American Urological Association recommends that recovery of normal spermatogenesis typically requires 6 months or longer after cessation of exogenous testosterone or anabolic steroids 14
• The Endocrine Society suggests that treatment of hyperprolactinemia depends on etiology, with dopamine agonists for prolactinomas, or addressing medication-induced causes 13

Monitoring and Complications Management

• The American College of Physicians recommends monitoring testosterone levels every 3-6 months initially, then annually once stable 15
• The American Heart Association suggests checking hematocrit regularly, with intervention required if Hct exceeds 54% (phlebotomy, dose adjustment if on any therapy) 10, 11, 12
• The American College of Cardiology recommends monitoring lipid profile and cardiovascular risk factors, as elevated testosterone increases atherosclerosis risk and causes adverse lipid changes 12
• The American Society for Reproductive Medicine suggests counseling patients about fertility implications, as elevated testosterone can suppress spermatogenesis through negative feedback on gonadotropins 13, 14
• The National Comprehensive Cancer Network recommends performing digital rectal examination and PSA testing at baseline and during follow-up, with low threshold for prostate biopsy if PSA rises substantially or examination becomes abnormal 15

Fertility Evaluation Prior to Treatment in Women with Elevated Testosterone

Fertility Considerations

• Prior to initiating any therapy that could further affect reproductive function, women with elevated testosterone should undergo a comprehensive fertility assessment to inform treatment planning and preserve reproductive potential. 16

Diagnostic Criteria and Evaluation of Hyperandrogenism in Women

Hormonal Thresholds and Ratios

• An LH/FSH ratio greater than 2 is indicative of polycystic ovary syndrome (PCOS), whereas an FSH level exceeding 35 IU/L suggests ovarian failure. 17
• A fasting morning prolactin concentration above 20 µg/L warrants pituitary magnetic‑resonance imaging to exclude a prolactinoma. 17
• Total testosterone levels above 2.5 nmol/L (approximately 72 ng/dL) are considered abnormal and should trigger further investigation. 17
• Androstenedione concentrations exceeding 10.0 nmol/L raise concern for an adrenal or ovarian androgen‑secreting tumor. 17
• Age‑specific DHEA‑S cut‑offs—greater than 3 800 ng/mL in women aged 20‑29—are suggestive of non‑classic congenital adrenal hyperplasia. 17
• A mid‑luteal progesterone value below 6 nmol/L indicates anovulation. 17
• A glucose‑to‑insulin ratio greater than 4, or a fasting glucose level above 7.8 mmol/L, points toward insulin resistance commonly associated with PCOS. 17

Imaging Findings

• Transvaginal pelvic ultrasound performed in the early follicular phase showing more than 10 peripheral ovarian cysts (2–8 mm) together with thickened ovarian stroma confirms the presence of polycystic ovaries. 17

Epidemiology and Clinical Characteristics

• PCOS affects roughly 4 – 6 % of the general female population and represents the leading cause of hyperandrogenism and anovulatory infertility in young women. 17
• The syndrome is characterized by an LH/FSH ratio > 2, modestly elevated testosterone, insulin resistance, and polycystic ovarian morphology on ultrasound. 17
• Isolated polycystic ovarian morphology—without hormonal abnormalities or symptoms—occurs in about 17 %– 22 % of otherwise normal women. 17

Menstrual and Ovulatory Assessment

• Menstrual patterns that merit evaluation include cycles shorter than 23 days (polymenorrhea), longer than 35 days (oligomenorrhea), or absence of bleeding for more than 6 months (amenorrhea). 17
• Low mid‑luteal progesterone (as noted above) confirms anovulation and should prompt targeted management. 17